EVO100 Gel
Phexxi + OB-002
- User: Female
- Hormonal: Non-Hormonal
-
Delivery type:
- Vaginal Gel
-
Intended Duration:
- Pericoital
- Development Stage: Phase III
- Developer(s)/researcher(s): EvoFem
Details
- API: OB-002, Citric Acid, Lactic Acid
- Target: CCR5
-
Mechanism of Action:
- Inhibition of Sperm Motility
- Inhibition of Sperm Capacitation
- Inactive Materials: Undetermined
- Regimen: On Demand
- MPT: Potential MPT
Product Status
Developer has publicly confirmed that development has halted
History
Evofem initiated a Ph III study of their candidate MPT, EVO100, which combines their FDA approved product Phexxi with a CCR5 antagonist OB-002, in 2020. Ultimately, the study did not achieve its target endpoints and the company announced discontinuation of the development platform.